1. Du, Kailong, Sun, Shijie, Jiang, Tinghui, Wang, Yitao, Bu, Youquan. 2022. E2F2 promotes lung adenocarcinoma progression through B-Myb- and FOXM1-facilitated core transcription regulatory circuitry. In International journal of biological sciences, 18, 4151-4170. doi:10.7150/ijbs.72386. https://pubmed.ncbi.nlm.nih.gov/35844795/
2. Shang, Yuanyuan, Zhang, Yuanyuan, Liu, Jie, Lu, Bing, Fu, Chuan-Gang. 2022. Decreased E2F2 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Colorectal Cancer. In Journal of Cancer, 13, 653-668. doi:10.7150/jca.61415. https://pubmed.ncbi.nlm.nih.gov/35069909/
3. Liu, Hongfei, Chen, Liping, Xiao, Wanli, Yang, Lin, Chen, Shenghan. 2022. Alteration of E2F2 Expression in Governing Endothelial Cell Senescence. In Genes, 13, . doi:10.3390/genes13091522. https://pubmed.ncbi.nlm.nih.gov/36140689/
4. Cao, Jian, Wang, Huan, Liu, Guangquan, Gu, Xiaoyan, Han, Suping. 2020. LBX2-AS1 promotes ovarian cancer progression by facilitating E2F2 gene expression via miR-455-5p and miR-491-5p sponging. In Journal of cellular and molecular medicine, 25, 1178-1189. doi:10.1111/jcmm.16185. https://pubmed.ncbi.nlm.nih.gov/33342041/
5. Shen, Shen, Wang, Yanfang. 2021. Expression and Prognostic Role of E2F2 in Hepatocellular Carcinoma. In International journal of general medicine, 14, 8463-8472. doi:10.2147/IJGM.S334033. https://pubmed.ncbi.nlm.nih.gov/34824545/